EGFR and incontinentia pigmenti: performed an analysis of adverse events reported through the FDA adverse event reporting system and compared the incidence of interstitial pneumonitis (IP) between patients treated with and EGFR TKI, nivolumab, or combination nivolumab + EGFR TKI (130).